巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

NRX Pharmaceuticals

NRXP
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・NRX Pharmaceuticals - 延遲價格・最後更新於 14/01 12:14
最高位
4.470
最低位
4.320
開市價
--
前收市價
4.370
成交量(千)
31.21
成交額(百萬)
1.01
買入
--
賣出
--
每手股數
--
市值(百萬)
256.41
市盈率
--
息率
--
差價
--
52週高低
76.990 - 4.070
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
NRX Pharmaceuticals
證券代碼
NRXP.US
所屬板塊
Biotechnology
公司業務
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
發行量
47459958
公司總部
2645 N. Federal Highway, Suite 230
公司網址
https://nrxpharma.com
公司電話
+1 310 734-2300
暫無內容

關於

NRX Pharmaceuticals(NRXP.US)所屬的行業板塊為Biotechnology。
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
詳細公司背景可參考: https://nrxpharma.com